SCHEMBL3408545

SCHEMBL3408545

CC(N)Cc1ccc(-c2nc(Nc3ccc(CCN4CCOCC4)cc3)ncc2C#N)cc1

nearest known ligand 0.76

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 18/20 0.76
KDR P35968 18/20 0.76
CAMK2D Q13557 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14816373 0.88 CDK1 (0.74) CDK1KDR
SCHEMBL14816370 0.88 CDK1 (0.74) CDK1KDRCAMK2D
SCHEMBL20817055 0.87 CDK1 (0.76) CDK1KDRCAMK2D
SCHEMBL490791 0.86 CDK1 (1.00) CDK1KDR
SCHEMBL6034007 0.79 CDK1 (0.65) CDK1KDRCAMK2D
SCHEMBL6033288 0.79 CDK1 (1.00) CDK1KDR
SCHEMBL6033997 0.78 CDK1 (0.73) CDK1KDR
SCHEMBL6033306 0.78 CDK1 (0.87) CDK1KDR
SCHEMBL6033958 0.77 KDR (0.98) CDK1KDR
SCHEMBL4327703 0.74 CDK1 (1.00) CDK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4240368-A1 METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES MAX Biopharma, Inc. (US) 2023-09-13 EP disclosed
WO-2022098907-A1 METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES MAX BioPharma, Inc. (US) 2022-05-12 WO disclosed
WO-2015195684-A2 SMALL MOLECULE ANTI-SCARRING AGENTS UNIVERSITY OF ROCHESTER (US) 2015-12-23 WO disclosed
EP-2262530-A1 METALLOPROTEINASE 12 BINDING PROTEINS Dyax Corp. (US) 2010-12-22 EP disclosed
EP-2262840-A2 METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS Dyax Corp. (US) 2010-12-22 EP disclosed
WO-2009111507-A1 METALLOPROTEINASE 12 BINDING PROTEINS DYAX CORP. (US) 2009-09-11 WO disclosed
WO-2009111508-A2 METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS DYAX CORP. (US) 2009-09-11 WO disclosed
WO-2009097397-A2 METALLOPROTEINASE BINDING PROTEINS DYAX CORP. (US) 2009-08-06 WO disclosed
EP-2073826-A2 SEQUENTIAL COMBINATION THERAPY Dyax Corporation (US) 2009-07-01 EP disclosed
EP-1984522-A2 METHODS OF INCREASING LYMPHATIC FUNCTION The General Hospital Corporation (US) 2008-10-29 EP disclosed
WO-2008048996-A9 SEQUENTIAL COMBINATION THERAPY DYAX CORP (US) 2008-09-12 WO disclosed
WO-2008048996-A2 SEQUENTIAL COMBINATION THERAPY DYAX CORP. (US) 2008-04-24 WO disclosed
WO-2007084599-A2 METHODS OF INCREASING LYMPHATIC FUNCTION THE GENERAL HOSPITAL CORPORATION (US) 2007-07-26 WO disclosed
EP-1807451-A2 HK1-BINDING PROTEINS Dyax Corporation (US) 2007-07-18 EP disclosed
WO-2006017538-A9 HK1-BINDING PROTEINS DYAX CORP (US) 2006-03-30 WO disclosed
WO-2006017538-A2 HK1-BINDING PROTEINS DYAX CORP. (US) 2006-02-16 WO disclosed
WO-2005097187-A2 METHODS OF PREVENTING UVB-INDUCED SKIN DAMAGE THE GENERAL HOSPITAL CORPORATION (US) 2005-10-20 WO disclosed